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Abstract 
Context and objective: Growth hormone (GH) therapy increases growth and adult 
height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen 
oxandrolone (Ox) to GH is unclear.
Design and participants: A randomized, placebo-controlled, double-blind, dose-
response study was performed in ten centers in the Netherlands. One hundred 
thirty-three patients with TS were included in age group 1 (2-7.99 years), 2 (8-
11.99 years), or 3 (12-15.99 years). Patients were treated with GH (1.33 mg/m2/
day) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg/day) or 
conventional (0.06 mg/kg/day) dose from the age of eight, and estrogens from the 
age of twelve years. Adult height gain (adult height minus predicted adult height) and 
safety parameters were systematically assessed. 
Results: Compared with GH+Pl, GH+Ox 0.03 increased adult height gain in the 
intention-to-treat analysis (mean±SD, 9.5±4.7 vs. 7.2±4.0 cm, P=0.02) and per-
protocol analysis (9.8±4.9 vs. 6.8±4.4 cm, P=0.02). Partly due to accelerated bone 
maturation (P<0.001), adult height gain on GH+Ox 0.06 was not significantly different 
from that on GH+Pl (8.3±4.7 vs. 7.2±4.0 cm, P=0.3). Breast development was slower 
on GH+Ox (GH+Ox 0.03, P=0.02; GH+Ox 0.06, P=0.05), and more girls reported 
virilization on GH+Ox 0.06 than on GH+Pl (P<0.001).
Conclusions: In GH-treated girls with TS, we discourage the use of the conventional 
Ox dosage (0.06 mg/kg/day) because of its low benefit to risk ratio. The addition of 
Ox 0.03 mg/kg/day modestly increases adult height gain and has a fairly good safety 
profile, except for some deceleration of breast development.  
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Introduction
Turner syndrome (TS) is a disorder in females that is caused by the complete or 
partial absence of the second sex chromosome. It is one of the most common 
chromosomal disorders, affecting approximately one in 2000 live-born girls (1). 
Untreated adult patients are on average 20 cm shorter than healthy women (2), 
mainly due to haploinsufficiency of the Short stature HomeobOX-containing (SHOX) 
gene (3). Growth hormone (GH) therapy increases adult height with 5 to 12 cm (4-6), 
and the addition of the weak androgen oxandrolone (Ox) may further increase adult 
height (7-9). However, in previous studies Ox dosages of 0.1 mg/kg/day or greater 
had to be lowered to 0.05 and 0.06 mg/kg/day (7-9) on the frequent findings of 
virilizing side effects and increased bone maturation. Although the recommended 
Ox dosage is nowadays 0.05 mg/kg/day or less (10), the efficacy and safety of such 
dosage is unclear. We hypothesized that, due to the effect of Ox on bone maturation, 
the optimal dosage with respect to final height gain could be lower than 0.06 mg/kg/
day, and therefore performed a dose-response study. In this randomized, placebo-
controlled, double-blind study we assessed the benefit to risk ratio of Ox at a low 
(0.03 mg/kg/day) and previously conventional dosage (0.06 mg/kg/day) in GH-
treated girls with TS. 
Methods
Participants 
 Participants were recruited in ten pediatric endocrine centers in the Netherlands 
from December 1991 to June 2003. Inclusion criteria were a karyotype associated 
with TS (except for cytogenetical evidence of Y-chromosomal material); a calendar 
age between 2.00 and 15.99 years; and a bone age younger than 12.00 years (11). 
Exclusion criteria were growth failure due to other causes; use of drugs that could 
interfere with growth; and previous GH, sex hormone, or androgen therapy. The 
study was performed in accordance with the World Medical Association Declaration 
of Helsinki and approved by the ethics committee of each participating center. Before 
enrollment, written informed consent was obtained for each patient.
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Treatment
 Patients were included in age group 1 (2.00-7.99 years), 2 (8.00-11.99 years), or 3 
(12.00-15.99 years). After stratification for calendar age and height SD score (SDS) 
(12), they were randomized by a computer-generated schedule with a block size of 
six, and blindly assigned to receive, orally at bedtime after reaching the age of 8 years, 
Ox 0.03 mg/kg/day (Ox 0.03) (S.p.A., Milano, Italy), Ox 0.06 mg/kg/day (Ox 0.06), or 
a similar appearing placebo (Pl). The capsules were manufactured and distributed 
by one hospital pharmacy. All patients and doctors were blinded for the allocation 
of the patients, and will remain so until the last patient will finish the study. Only the 
independent pharmacist (dr. C.M.A. Rademaker), the statistician (M.A.d.R.), and data 
analyst (L.A.M., from 2008 onward) saw unblinded data, but none of them had any 
contact with the participants. From baseline onward, biosynthetic human GH (1.33 
mg/m2 body-surface/day, at 1 m2 equivalent to 46 µg/kg/day) was administered 
subcutaneously at bedtime. Genotropin (Pfizer Inc., New York, NY) was used in age 
groups 1 and 2, and Humatrope (Eli Lilly, Indianapolis, IN) in age group 3. Ox/Pl was 
started at the age of eight after a number of years GH therapy (i.e. at their main year-
visit) in age group 1, and at inclusion in age groups 2 and 3 (i.e. between the age of 
8.0 and 16.0 years). In the absence of spontaneous puberty (Tanner breast stage < 
2 (B2) (13)), estrogen therapy was started between the age of 12.0 and 12.99 (after 
a number of full years of GH therapy) in age groups 1 and 2, and at inclusion (i.e. 
between the age of 12 and 16 years) in age group 3. 17-ß-Estradiol was prescribed in 
age groups 1 and 2, and ethinyl-estradiol in age group 3 (5 and 0.05 mg/kg/day orally, 
increased to 10 and 0.1 mg/kg/day after two years, respectively). When ethinyl-
estradiol became unavailable after March 2002, 17-ß-estradiol was also prescribed 
in age group 3. Cyclic progesterone was added after at least two years of estrogen 
therapy. Doses were adjusted every six months, and GH+Ox/Pl were stopped when 
height velocity was less than 1 cm per six months, or when patients decided to stop 
because they were satisfied with their height. Thereafter, patients were followed for 
two subsequent year-visits to measure growth after discontinuing GH+Ox/Pl. 
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Assessments
Two trained observers performed all half-yearly measurements during the total 
study period. The primary outcome was adult height gain (cm), defined as adult 
height (the last measured height after discontinuing GH+Ox/Pl) minus predicted 
adult height, calculated using the modified projected adult height method (mPAH) 
(14). Briefly, Lyon et al. (15) used longitudinal heights of untreated TS girls to modify 
the projected adult height (which assumes that adult height SDS is equal to height 
SDS at a younger age) into a regression equation predicting adult height in TS. 
Adapted to North European girls with TS (2), this equation is: mPAH = 146.95 + 6.37 
x (-0.2 + 0.836 x height SDS at baseline) (14, 16). Height was measured at every visit 
using a Harpenden stadiometer. The mean of four measurements was expressed as 
SDS for healthy Dutch girls (17) and untreated Northern European girls with TS (2) 
using Growth Analyser (www.growthanalyser.org). To avoid overestimation of adult 
height SDS in patients who stopped growing at an earlier age than healthy peers or 
untreated girls with TS, reference data for the age of 21 instead of the actual age 
were used for calculating adult height SDS. Target height (cm) corrected for sex and 
secular trend was defined as: 0.5 x (height
maternal
 + height
paternal
- 13) + 4.5 (17). 
Secondary outcomes included the influence of age group on the effect of Ox, and 
the effect of Ox on: short-term height gain, adult height gain adjusted for bone age 
at start, safety parameters, pubertal development, bone maturation, and duration 
and costs of GH therapy. To assess bone maturation (Δbone age / Δcalendar age), 
one trained, and up until 2008 blinded investigator (L.A.M.) determined bone ages 
of the yearly made hand x-rays retrospectively and chronologically according to the 
Tanner and Whitehouse radius, ulna, short-bones score (11). Pubertal stages were 
assessed half-yearly according to Tanner (13) and expressed as SDS adjusting for age 
and sex (18). The cumulative amount of GH prescribed was multiplied by 44.32 euro/
mg (Genotropin, www.fk.cvz.nl, 2009) to obtain cumulative costs of GH therapy. 
All adverse events reported by the patient, parent, or medical doctor were 
registered. Virilizing adverse events included voice deepening, clitoral enlargement, 
or an increase in body hair, all being previously identified as Ox-related virilization (7-
9, 19). These events were included in the analysis if a girl reported virilization at least 
twice (i.e. either the same complaint at two visits or two complaints at one visit) or if 
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the girl decided to discontinue Ox/Pl because of the event. Dynamap blood pressure 
(BP) monitoring was performed half yearly. The latter three of four measurements 
were averaged and expressed as SDS adjusting for age, gender and height (20). Blood 
samples were taken at starting GH, after six months, yearly, and six months after 
discontinuing GH+Ox/Pl. Determinations included plasma IGF-I, IGF binding protein 
(IGFBP)-3, glycosylated hemoglobin (HbA1c), aspartate aminotransferase (ASAT), 
alanine aminotransferase (ALAT), free T
4
, and TSH. IGF-I, IGFBP-3, and HbA1c levels 
were determined in a central laboratory. IGF-I was measured by RIA from 1991 to 
2000, an immunometric technique on an Advantage chemiluminescense system 
from 2000 to 2006 (Nichols Institute Diagnostics, San Juan Capistrano, CA), and an 
immunometric technique on an IMMULITE 1000 Analyzer from 2006 to 2008 (Siemens 
Medical Solutions Diagnostics, Los Angeles, CA), which produced identical results. 
IGFBP-3 was measured using a chemoluminescence based immunometric technique 
(IMMULITE 2000, Siemens Medical Solutions). IGF-I and IGF-I to IGFBP-3 molar 
ratio were transformed into SDS using reference levels for healthy Dutch children 
(21). HbA1c levels were measured using a dedicated automatic high pressure liquid 
chromatography analyzer (DIAMAT from 1991 to 1997, and VARIANT from 1997 to 
2008, Bio-Rad Laboratories, Inc., Edgemont, CA). Both methods produced identical 
results (upper normal assay limit < 6.6%).
Statistical analyses
We estimated that 15 patients per dosage and age group were needed to achieve a 
power of 80% to detect a difference (P=0.05, two sided) in first-year height velocity 
of 2 cm with an assumed SD of 2.6. Intention-to-treat analyses were performed and 
differences in adult height gain were also assessed by a per-protocol analysis. Safety 
parameters were assessed in a modified intention-to-treat analysis, in which patients 
who refused to start Ox/Pl therapy were excluded. When Ox/Pl was discontinued 
before discontinuing GH, the moment at which GH was discontinued was identified as 
at discontinuing GH+Ox/Pl. Differences between dosage groups were tested by linear 
regression using two dummies (for GH+Ox 0.03 and GH+Ox 0.06) and differences 
in proportions by Pearson χ2 tests and Fisher’s exact tests. Means were compared 
with zero by a one-sample t test. Differences in change of outcome variables during 
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the study period were assessed by repeated-measurements analysis. Models were 
fitted with a different intercept and slope per dosage group and a random intercept 
and slope per patient. To assess the influence of the age groups, interaction terms 
between age groups and dosage groups were used. 
Figure 1. Enrollment, randomization and analysis of the patients. 
Ox/Pl, oxandrolone/placebo; IGT, impaired glucose tolerance. Some patients were excluded 
from the per-protocol analysis for more than one reason, the sum of these numbers may 
therefore not equal the total number of patients in these boxes. 
184 Patients were assessed for eligibility
51 Were excluded 
19 Had a bone age > 12 yr 
13 Had Y chromosomal material
6 Had used drugs which could 
negatively influence growth
13 refused to participate
133 Underwent randomization
48 Were assigned to receive GH 
+ placebo
46 Were assigned to receive GH 
+ oxandrolone 0.03 mg/kg/day
39 Were assigned to receive GH 
+ oxandrolone 0.06 mg/kg/day
2 Were lost to follow-up 2 Were lost to follow-up 0 Were lost to follow-up
4 Have yet to reach adult 2 Have yet to reach adult 3 Have yet to reach adult 
height height height
42 Were included in the 
intention-to-treat analysis
42 Were included in the 
intention-to-treat analysis 
36 Were included in the 
intention-to-treat analysis
(including 1 girl aged 1.3 yrs)
12 Were excluded 12 Were excluded 14 Were excluded
4 Refused to start Ox/Pl 4 Refused to use Ox/Pl 3 Used more estrogens
8 Used more estrogens 3 Used more estrogens than intended 
1 Reported to be non-than intended 
3 Reported to be non-
than intended 
1 Reported to be non- compliant
compliant compliant 1 Used Lucrin therapy
3 Discontinued GH and 9 Discontinued Ox/Pl  
prematurely due toOx/Pl prematurely
1 Lack of motivation 1 Hypertension
1 IGT 1 Problems with
1 Crohn’s disease swallowing the    
capsule2 Discontinued Ox/Pl  
prematurely due to 7 Virilization   
1 Depression
1 Virilization
30 Were included in the per-
protocol analysis
30 Were included in the per-
protocol analysis
22 Were included in the per-
protocol analysis
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Results
Patient characteristics
Fig. 1 shows the 133 patients that were randomized. Four patients were lost to 
follow-up and nine patients were still treated when the analysis started in May 2008. 
Of the 120 patients included in the intention-to-treat analysis, the parents of eight 
girls refused Ox/Pl because of fear of side effects and/or satisfaction with growth. 
After excluding all protocol-violators, 82 patients (68%) were left for the per-protocol 
analysis.
Adult height gain
Baseline data were similar between the dosage groups (Table 1). Fig. 2 shows the 
height SDS before, during and after discontinuing GH+Ox/Pl therapy. The two-year 
increase in height SDS was significantly greater on GH+Ox 0.03 and 0.06 than on 
GH+Pl (P<0.001 for both comparisons), but differences decreased before reaching 
adult height. Fig. 3 shows the individual heights of the 120 girls at starting GH 
therapy, as well as after reaching adult height. Adult height gain, measured 1.9±0.8 
years after discontinuing GH, was greater than zero in each dosage group (P<0.001 
for all comparisons) (Fig. 4). Compared with GH+Pl, it was 2.3 cm greater on GH+Ox 
0.03 (95% confidence interval (CI), 0.4 to 4.2, P=0.02), and 1.2 cm greater on GH+Ox 
0.06 (95% CI, -0.8 to 3.2, P=0.3) (Fig. 4A). Similar results were obtained when leaving 
out the eight patients that did not start Ox/Pl therapy (data not shown), and when 
analyzing the increase in height SDS from baseline to adulthood (Table 2). When 
correcting for bone age at starting GH therapy, the difference in adult height gain 
compared with GH+Pl was 1.8 cm on GH+Ox 0.03 (P=0.05), and 1.0 cm on GH+Ox 
0.06 (P=0.3). In the per-protocol analysis, adult height gain was 3.1 cm greater on 
GH+Ox 0.03 (95% CI, 0.5 to 5.6, P=0.02) and 2.2 cm greater on GH+Ox 0.06 (95% CI, 
-0.6 to 4.9, P=0.1) (Fig. 4B). 
 Bone maturation was greater in both GH+Ox groups than on GH+Pl (GH+Ox 0.03, 
P=0.007; GH+0.06, P<0.001) (Table 2). When corrected for bone age at starting GH, 
the duration of GH therapy was shorter on GH+Ox 0.03 and 0.06 (-0.4 years and 
-0.8 years, P=0.06 and P=0.001, respectively), and the cumulative costs of GH were 
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lower (-10,100±6,100 and -13,500±6,300 euro, P=0.1 and P=0.03, respectively) than 
on GH+Pl (mean cumulative costs, 161,200±59,500 euro). 
Supplemental Table 1 shows the baseline and clinical data per age group and per 
dosage group. In the intention-to-treat analysis, mean adult height gain in age groups 
1, 2, and 3 was 9.4±4.4, 6.0±3.6, and 5.8±2.6 cm on GH+Pl; 10.4±5.8, 9.0±4.4, and 
8.6±3.0 cm on GH+Ox 0.03; and 10.0±3.7, 9.0±4.8, and 5.4±4.7 cm on GH+Ox 0.06, 
respectively. Among the three age-groups, no statistically significant difference in the 
effect of Ox on adult height gain was found.
Pubertal development
Puberty started spontaneously in 28 girls (mean age at B2, 11.1±1.0 years). In the 
remaining 92 girls, estrogen therapy was started at a mean age of 12.8±0.9 years. In 
the years thereafter, breast stage SDS of the girls that had started Ox/Pl (modified 
intention-to-treat analysis, n=112) increased less on GH+Ox 0.03 and 0.06 than on 
GH+Pl (during first 2 years, P=0.05 and 0.1, respectively; until discontinuing GH+Ox/
Pl, P=0.02 and 0.05, respectively) (Table 2). Breast stage SDS at discontinuing Ox/Pl 
was lower on GH+Ox 0.03 than on GH+Pl (P=0.01) and although it caught up after 
discontinuing Ox and increasing estrogen dosages, it was still lower on GH+Ox 0.03 
than on GH+Pl after discontinuing GH+Ox/Pl (P=0.04) (Table 2). Pubic hair stage SDS 
increased significantly more on GH+Ox 0.03 and 0.06 than on GH+Pl during the first 
two years of Ox/Pl (P=0.008 and 0.003, respectively), but the increase during the 
total duration of Ox/Pl therapy was not significantly different between the dosage 
groups (Table 2). Mean pubic hair stage SDS at discontinuing Ox/Pl was, however, 
significantly greater on GH+Ox 0.06 than on GH+Pl (P=0.003).
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Figure 2. Height SDS during the study compared with untreated Northern European girls with 
Turner syndrome (upper part) and healthy Dutch girls (lower part).
Symbols represent means±SD; Ox/Pl, oxandrolone/placebo. Note that Ox/Pl therapy was 
started between the age of 8.0 to 8.99, after a number of years of GH therapy in age group 
1, and at inclusion (i.e. between the age of 8 and 16 years) in age groups 2 and 3. Height 
SDS at starting GH therefore reflects untreated values, whereas height SDS at starting Ox/Pl 
includes values from girls that had already been treated with GH. Height SDS at the last visit 
was calculated using reference values for 21-year-old girls. The asterisk indicates that mean 
first two-year increase in height SDS was greater than on GH+Pl (P<0.001).
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Figure 4. Adult height gain in the intention-to-treat analysis (A) and per-protocol analysis (B).
Diamonds represent adult height gain (adult height minus predicted adult height) of the 
individual patients; lines represent mean adult height gain per dosage group. Mean adult 
height gain was greater than zero in each dosage group (P<0.001 for all comparisons in both 
analyses). Compared with GH+Pl, adult height gain was greater on GH+Ox 0.03 (P=0.02 both 
in the intention-to-treat analysis and per-protocol analysis), and not significanlty greater on 
GH+Ox 0.06. 
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Adverse events and virilization
During the study, 2030 adverse events were reported, none of which were considered 
GH related. Twenty-three girls reported a total of 40 virilizing adverse events (Table 2), 
and more girls on GH+Ox 0.06 than on GH+Pl reported virilization (P<0.001). One girl 
on GH+Ox 0.03 and seven on GH+Ox 0.06 (vs. zero on GH+Pl, P=0.005) discontinued 
Ox because of virilization. After discontinuing Ox/Pl, two girls (from groups GH+Ox 
0.03 and 0.06) still reported hirsutism, and one girl (from group GH+Ox 0.06) still 
reported having a low voice. However, hirsutism relieved in three girls, subjective 
voice deepening relieved in two girls (all from group GH+Ox 0.06), and clitoral 
size appeared less in two girls (from group GH+Ox 0.03). The other complaints of 
virilization were not reported anymore.
Blood pressure
Mean systolic and diastolic BP (Tables 1 and 2) was significantly higher than in healthy 
girls, at both starting and discontinuing GH+Ox/Pl (P<0.001 for all comparisons). 
During Ox/Pl, systolic BP SDS tended to decrease somewhat more on GH+Ox 0.06 
than on GH+Pl (P=0.06), whereas changes in diastolic BP SDS were not significantly 
different between the dosage groups (Table 2). 
Biochemical evaluation
Compared with GH+Pl, mean IGF-I SDS just before discontinuing GH+Ox tended to 
be greater on GH+Ox 0.03 an 0.06 (corrected for values at starting Ox/Pl, P=0.09 and 
0.05, respectively), and the proportion of patients with an IGF-I greater than 2 SDS 
at least once during therapy was greater (GH+Ox 0.03, P=0.04; GH+Ox 0.06, P=0.06) 
(Table 2). The change of IGF-I SDS as well as IGF-I to IGFBP-3 ratio during the first 
year of Ox/Pl therapy was, however, not significantly different between the dosage 
groups (Table 2). 
After starting Ox/Pl, five girls had intermittently elevated ASAT and/or ALAT levels 
(Table 2), and five girls (three on GH+Ox 0.03 and two on GH+Ox 0.06) developed 
hypothyroidism and started thyroxine supplementation. 
One girl, who already had an impaired glucose tolerance at baseline, had impaired 
glucose tolerance and an elevated HbA1c (7.7%) after two years of GH+Ox 0.03 
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therapy. She therefore discontinued GH+Ox, after which HbA1c and glucose levels 
returned to normal. The HbA1c levels of all other girls remained normal, and none of 
the girls developed diabetes mellitus type 1 or 2.
Discussion
In the past two decades, several trials suggested that the addition of Ox to GH 
positively affected adult height in girls with TS (7-9). However, these studies enrolled 
smaller numbers of patients, were neither randomized nor placebo controlled, and 
had to lower their Ox starting dosages (≥ 0.1 mg/kg/day) on the frequent finding 
of virilizing adverse events. Our randomized, placebo-controlled, double-blind study 
shows that GH combined with Ox at a previously not studied low dosage (0.03 mg/
kg/day) moderately increases adult height gain and has an acceptable safety profile 
except for a small deceleration in breast development. The addition of the previously 
conventional Ox dosage (0.06 mg/kg/day) does not significantly increase adult height 
gain and causes virilization in a large proportion of patients.
During the first two years after starting Ox/Pl, the increase in height SDS on 
GH+Ox 0.03 and 0.06 was significantly greater than on GH+Pl. Adult height gain on 
GH+Ox 0.06 was, however, smaller than on GH+Ox 0.03, which may be explained by 
the relatively frequent premature discontinuation of Ox 0.06 because of virilization, 
and the increase in bone maturation with increasing Ox dosages. In contrast, the 
growth-promoting effect of GH+Ox 0.03 outweighed the increase in bone maturation, 
resulting in an increased adult height gain compared with GH+Pl. 
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The exact mechanism by which Ox increases bone growth and maturation is 
uncertain. A recent report showed that bone growth in vitro was not influenced by 
Ox, suggesting that Ox may mainly influence the growth plate in an indirect way (22). 
Ox does not appear to increase GH secretion (23), but it may increase growth by 
increasing IGF-I (presumably by increasing insulin-induced hepatic GH receptors) (24), 
by suppressing IGFBP-I (an inhibitor of IGF-I) (24), and/or by increasing free estrogen 
levels due to an Ox-induced decrease in SHBG (24, 25). Testosterone is thought to 
increase bone maturation primarily via the aromatase-induced local conversion 
to estradiol (25, 26). The increase in bone maturation due to the nonaromatizable 
androgen Ox, however, shows that androgens may also influence bone maturation 
either directly, or indirectly via other pathways (27).
We found that the addition of Ox to GH therapy delayed breast development 
to some extent. Although breast stage SDS caught up after discontinuing GH+Ox 
and increasing estrogen dosages, it was still lower on GH+Ox 0.03 than on GH+Pl. 
Particularly nonaromatizable androgens (such as Ox and dihydrotestosterone) are 
known to inhibit the stimulatory effect of estrogens on the mammary gland (28). This 
inhibitory effect may possibly be overcome by increasing estrogen dosages, although 
a further acceleration of bone maturation would then perhaps eliminate the positive 
effect of Ox on adult height. 
Several girls on GH+Ox 0.06 reported virilization, and about half of them 
decided to discontinue Ox for that reason. The finding that also some girls on 
GH+Pl complained of virilization reflects that part of the reported virilization may 
be regarded physiological and/or that patients tended to report virilization because 
they knew this could be a consequence of Ox. Whereas hirsutism and clitoromegaly 
seem to regress after discontinuing Ox (9, 19), voice deepening appears irreversible 
(29). 
 Several other adverse events were scarce. As expected in adolescents with TS, 
a few patients developed hypothyroidism (30). Although Ox at higher dosages may 
elevate liver enzymes in non-TS patients (31), we did not find such an effect at the 
dosages we studied. We furthermore found that the addition of Ox did not increase 
diastolic BP, whereas systolic BP even tended to decrease on GH+Ox 0.06 vs. GH+Pl. 
One patient discontinued GH+Ox 0.03 because of an increased HbA1c and an impaired 
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glucose tolerance, after which HbA1c and glucose levels returned to normal. Patients 
with TS are at an increased risk of developing insulin resistance, and GH therapy, 
especially when combined with Ox ≥ 0.06 mg/kg/day, may increase this risk (24, 32, 
33). This effect, however, appeared to be reversible after discontinuation of therapy 
(34). IGF-I levels were more frequently increased on GH+Ox than on GH+Pl, whereas 
the increase in IGF-I levels and IGF-I to IGFBP-3 ratio (an indicator of free IGF-I) was 
not significantly different between the dosage groups. Previous studies also showed 
conflicting results regarding the effect of Ox on IGF-I levels and IGF-I to IGFBP-3 ratio 
(35, 36).
 The addition of Ox is not the only strategy to increase adult height gain in TS. Adult 
height gain may also be augmented by increasing GH dosages, rather than adding Ox 
to GH therapy (6). Increasing GH doses would, however, increase IGF-I levels (6) as 
well as costs, whereas our data show that Ox may lower the GH-associated costs. A 
further argument in favor of adding Ox is that it may result in a more physiological 
hormonal status, considering the androgen-insufficient state of untreated girls and 
women with TS (37, 38). Another strategy to increase adult height gain is to start GH 
therapy at a relatively young age. Our finding that mean adult height gain on GH+Pl 
was 9.4, 6.0, and 5.8 cm in age groups 1, 2, and 3, respectively, confirms that an early 
diagnosis and start of GH therapy positively influences adult height gain (6). 
 Our study has some limitations. First, although it included a follow-up period of 
1.9±0.8 years after discontinuation of GH+Ox/Pl, a longer follow-up would be needed 
to assess long-term safety. Second, we did not study quality of life and well-being. 
We hypothesize that the observed delay in breast development may negatively 
affect these parameters, whereas the increase in height during therapy as well as 
the decrease in duration of GH therapy (i.e. subcutaneous injections) may have some 
positive effects. Compensating the androgenic insufficiency in TS may also have some 
positive effects, similar to the effect on well-being observed in androgen-treated 
adult patients with TS (39). Finally, no standardized scoring system was used in the 
assessment of the virilizing adverse events. Consequently, the reported virilization 
may underestimate the actual occurrence of virilization. Because we were unable 
to compare the girls with healthy girls in puberty, it is additionally unclear whether 
the reported virilization should be regarded as genuine virilization or a normalization 
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from an androgen-insufficient state. The relatively great number of patients that 
discontinued Ox 0.06 due to virilization, however, suggests that this dosage indeed 
results in virilization. 
 We conclude that in GH-treated girls with TS, Ox in a conventional dose (0.06 
mg/kg/day) has limited efficacy, and gives rise to virilizing side effects. We therefore 
discourage its use. The addition of low-dose Ox (0.03 mg/kg/day) modestly increases 
adult height gain and has a fairly good safety profile, except for a small deceleration 
in breast development. In patients considering this deceleration less important than 
the increment in height gain, Ox 0.03 mg/kg/day may be added to GH to increase 
height.
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Supplemental Table 1. Baseline and adult height data per age group and dosage 
group.*
* Plus-minus values are means ±SD. 
† No statistical tests were applied.
‡ Percentages may not total 100 because of rounding.  
¶ Adult height SDS was calculated using reference values for 21-year-old girls.
║ Defined as adult height minus predicted adult height.
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